[目的]观察补肺益肾方对肺肾气虚型慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期患者肺康复的作用。[方法]搜集2021年10月至2023年1月浙江医院确诊的肺肾气虚型COPD稳定期患者55例,随机分成试验组(26例)和对照...[目的]观察补肺益肾方对肺肾气虚型慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期患者肺康复的作用。[方法]搜集2021年10月至2023年1月浙江医院确诊的肺肾气虚型COPD稳定期患者55例,随机分成试验组(26例)和对照组(29例)。对照组予稳定期吸入剂+肺康复运动训练治疗方案,试验组在此基础上予补肺益肾方加减治疗。评估两组患者治疗前,治疗第4周、第8周的肺功能指标第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)、第1秒用力呼气容积占预计值百分比(forced expiratory volume in the first second to predicted values,FEV1%)、第一秒用力呼气容积占用力肺活量比值(forced expiratory volume in one second to forced vital capacity,FEV1/FVC)、慢性阻塞性肺疾病评估测试(chronic obstructive pulmonary disease assessment test,CAT)评分、咳嗽能力评分、咳痰难度评分、体质量指数(body mass index,BMI),并监测患者不良反应情况。[结果]与本组治疗前比较,两组在治疗4周、8周,FEV1、FEV1%均有升高,CAT评分、咳嗽难度均有下降,差异均有统计学意义(P<0.05);BMI、咳嗽能力差异无统计学意义(P>0.05);试验组FEV1/FVC治疗4周差异无统计学意义(P>0.05),治疗8周升高,差异有统计学意义(P<0.05)。与对照组同期比较,试验组在治疗4周、8周,CAT评分降低、咳嗽难度下降,差异均有统计学意义(P<0.05),FEV1、FEV1%、咳嗽能力、BMI差异均无统计学意义(P>0.05);试验组FEV1/FVC在治疗4周差异无统计学意义(P>0.05),治疗8周升高,差异有统计学意义(P<0.05)。[结论]补肺益肾方在COPD稳定期患者中对肺康复起到协同作用。展开更多
原发性肝癌(PLC)是一种我国常见的恶性肿瘤,有较高的发生率和死亡率,目前西医主要采取外科手术治疗和消融治疗,虽然对肝癌症状具有一定疗效,但大多数患者发现已是中晚期,已经失去最佳治疗时机。近年来,随着中医药对原发性肝癌的研究日...原发性肝癌(PLC)是一种我国常见的恶性肿瘤,有较高的发生率和死亡率,目前西医主要采取外科手术治疗和消融治疗,虽然对肝癌症状具有一定疗效,但大多数患者发现已是中晚期,已经失去最佳治疗时机。近年来,随着中医药对原发性肝癌的研究日益增多,其不仅可以通过调整患者的体质,提高病人的免疫力,扶正固本,还可以通过外敷、口服中药汤剂、中药离子介入等方式结合治疗,通过调控体内信号传导方式来影响肝癌细胞因子,从而达到治疗肝癌相关疾病的作用。目前大部分文章都是以中医药防治肝癌为主,而缺乏通过信号通路以及发病机制的总结性研究。本文重点论述了近些年来中医药治疗肝癌相关信号通路的研究进展,即RaF/MEK/ERK通路、PI3K/AKT/mTOR通路、WNT/β-catenin通路、肝细胞生长因子/c-MET通路、生长因子调节的血管生成信号途径。通过阐述肝癌的发病机制,为治疗肝癌提供一些靶点和临床思路。Primary liver cancer (PLC) is a common malignant tumor in China, with a high incidence and mortality rate. At present, Western medicine mainly adopts surgical treatment and ablation treatment, although it has a certain effect on liver cancer symptoms, but most patients are found to be in the middle and advanced stages and have lost the best treatment opportunity. In recent years, with the increasing research on primary liver cancer in traditional Chinese medicine, it can not only improve the patient’s immunity by adjusting the patient’s physique, but also strengthen the foundation. It can also be combined with external application, oral Chinese medicine decoction, traditional Chinese medicine ion intervention, etc., to affect liver cancer cytokines by regulating the signal transduction mode in vivo, so as to achieve the effect of treating liver cancer-related diseases. At present, most of the articles focus on the prevention and treatment of liver cancer with traditional Chinese medicine, but there is a lack of summary research on signaling pathways and pathogenesis. This article discusses the research progress of TCM in the treatment of HCC-related signaling pathways, namely RaF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/β-catenin pathway, hepatocyte growth factor/c-MET pathway, and growth factor-regulated angiogenic signaling pathway. This article provides some targets and clinical ideas for the treatment of liver cancer by elaborating on the pathogenesis of liver cancer.展开更多
文摘[目的]观察补肺益肾方对肺肾气虚型慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期患者肺康复的作用。[方法]搜集2021年10月至2023年1月浙江医院确诊的肺肾气虚型COPD稳定期患者55例,随机分成试验组(26例)和对照组(29例)。对照组予稳定期吸入剂+肺康复运动训练治疗方案,试验组在此基础上予补肺益肾方加减治疗。评估两组患者治疗前,治疗第4周、第8周的肺功能指标第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)、第1秒用力呼气容积占预计值百分比(forced expiratory volume in the first second to predicted values,FEV1%)、第一秒用力呼气容积占用力肺活量比值(forced expiratory volume in one second to forced vital capacity,FEV1/FVC)、慢性阻塞性肺疾病评估测试(chronic obstructive pulmonary disease assessment test,CAT)评分、咳嗽能力评分、咳痰难度评分、体质量指数(body mass index,BMI),并监测患者不良反应情况。[结果]与本组治疗前比较,两组在治疗4周、8周,FEV1、FEV1%均有升高,CAT评分、咳嗽难度均有下降,差异均有统计学意义(P<0.05);BMI、咳嗽能力差异无统计学意义(P>0.05);试验组FEV1/FVC治疗4周差异无统计学意义(P>0.05),治疗8周升高,差异有统计学意义(P<0.05)。与对照组同期比较,试验组在治疗4周、8周,CAT评分降低、咳嗽难度下降,差异均有统计学意义(P<0.05),FEV1、FEV1%、咳嗽能力、BMI差异均无统计学意义(P>0.05);试验组FEV1/FVC在治疗4周差异无统计学意义(P>0.05),治疗8周升高,差异有统计学意义(P<0.05)。[结论]补肺益肾方在COPD稳定期患者中对肺康复起到协同作用。
文摘原发性肝癌(PLC)是一种我国常见的恶性肿瘤,有较高的发生率和死亡率,目前西医主要采取外科手术治疗和消融治疗,虽然对肝癌症状具有一定疗效,但大多数患者发现已是中晚期,已经失去最佳治疗时机。近年来,随着中医药对原发性肝癌的研究日益增多,其不仅可以通过调整患者的体质,提高病人的免疫力,扶正固本,还可以通过外敷、口服中药汤剂、中药离子介入等方式结合治疗,通过调控体内信号传导方式来影响肝癌细胞因子,从而达到治疗肝癌相关疾病的作用。目前大部分文章都是以中医药防治肝癌为主,而缺乏通过信号通路以及发病机制的总结性研究。本文重点论述了近些年来中医药治疗肝癌相关信号通路的研究进展,即RaF/MEK/ERK通路、PI3K/AKT/mTOR通路、WNT/β-catenin通路、肝细胞生长因子/c-MET通路、生长因子调节的血管生成信号途径。通过阐述肝癌的发病机制,为治疗肝癌提供一些靶点和临床思路。Primary liver cancer (PLC) is a common malignant tumor in China, with a high incidence and mortality rate. At present, Western medicine mainly adopts surgical treatment and ablation treatment, although it has a certain effect on liver cancer symptoms, but most patients are found to be in the middle and advanced stages and have lost the best treatment opportunity. In recent years, with the increasing research on primary liver cancer in traditional Chinese medicine, it can not only improve the patient’s immunity by adjusting the patient’s physique, but also strengthen the foundation. It can also be combined with external application, oral Chinese medicine decoction, traditional Chinese medicine ion intervention, etc., to affect liver cancer cytokines by regulating the signal transduction mode in vivo, so as to achieve the effect of treating liver cancer-related diseases. At present, most of the articles focus on the prevention and treatment of liver cancer with traditional Chinese medicine, but there is a lack of summary research on signaling pathways and pathogenesis. This article discusses the research progress of TCM in the treatment of HCC-related signaling pathways, namely RaF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/β-catenin pathway, hepatocyte growth factor/c-MET pathway, and growth factor-regulated angiogenic signaling pathway. This article provides some targets and clinical ideas for the treatment of liver cancer by elaborating on the pathogenesis of liver cancer.
